China special issue on gastrointestinal tumors‐Regulatory‐immunoscore—A novel indicator to guide precision adjuvant chemotherapy in colorectal cancer

Abstract Novel biomarkers are essential to improve the treatment efficacy and overall survival of stage II and III colorectal cancer (CRC), allowing for personalized treatment decisions. Here, the densities of CD8 + and FOXP3 + T cells in the tumor and invasive margin were processed by immunohistoch...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cancer 2023-12, Vol.153 (11), p.1904-1915
Main Authors:	Fang, Lin, Yao, Yang, Guan, Xin, Liao, Yuanyu, Wang, Bojun, Cui, Luying, Han, Shuling, Zou, Haoyi, Su, Dan, Ma, Yue, Liu, Biao, Wang, Yao, Huang, Rui, Ruan, Yuli, Yu, Xuefan, Yao, Yuanfei, Liu, Chao, Zhang, Yanqiao
Format:	Article
Language:	eng
Subjects:	Biomarkers Cancer CD8 antigen Chemotherapy Colorectal cancer Colorectal carcinoma DNA repair Foxp3 protein Immunohistochemistry Lymphocytes Lymphocytes T Medical research Mismatch repair Precision medicine Regression analysis Risk factors Survival analysis Tumors
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Novel biomarkers are essential to improve the treatment efficacy and overall survival of stage II and III colorectal cancer (CRC), allowing for personalized treatment decisions. Here, the densities of CD8 + and FOXP3 + T cells in the tumor and invasive margin were processed by immunohistochemistry and digital pathology to form a scoring system named regulatory‐Immunoscore (RIS). Cox proportional hazards regression models were used to determine the risk factors associated with time to recurrence. Harrell's concordance index and the time‐dependent area under the curve were used to assess model performance. A total of 1213 stage I‐III DNA mismatch repair‐proficient colorectal cancer (pMMR CRC) patients were randomly assigned to a training set (n = 642) and a validation set (n = 571). From the Cox multivariable analysis, the association of RIS with survival was independent of patient age, sex and anatomy‐based tumor risk parameters ( P < .0001). For stage II patients, chemotherapy was significantly associated with better recurrence time in patients with low (95% confidence interval [CI]: 0.11‐0.54, P = .001) and intermediate (95% CI = 0.25‐0.57, P < .001) RIS values. In stage III patients treated with adjuvant chemotherapy, a treatment duration of 6 or more months was significantly associated with better recurrence time in patients with intermediate RIS values (95% CI = 0.38‐0.90, P = .016) when compared with duration under 6 months. Therefore, these findings suggest that RIS is reliable for predicting recurrence risk and treatment responsiveness for patients with stage I‐III pMMR CRC.
ISSN:	0020-7136 1097-0215